



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

+

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

RECEIVED

Application Number	10/051,681
Filing Date	January 16, 2002
First Named Inventor	D. Cohen et al. JAN 24 2002
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	101.US5.REG

TECH CENTER 1600/2900

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RP	R85	CRUZ, L.J. et al., "Mutual antagonism in the metabolism of D-valine and D-leucine and antagonism by their analogs", <i>Arch Biochem Biophys.</i> , 1969, 135(1):341-9. PubMed, PMID: 4391341.	
RP	R86	DE KOK, A. et al., "Studies on L-amino acid oxidase. I. Effects of pH and competitive inhibitors", <i>Biochim Biophys Acta</i> , 1968, 167(1): 35-47, PubMed, PMID: 5693709.	
RP	R87	DE MARCHI, W.J. et al., "The oxidation of glycine by D-amino acid oxidase in extracts of mammalian central nervous tissue", <i>J Neurochem.</i> , 1969, 16(3):355-61. PubMed, PMID: 4389537.	
RP	R88	MCFARLANE, I.G. et al., "Metabolism of leucine in protein-calorie-deficient rats", <i>Biochem J.</i> , 1969, 111(4):565-71, PubMed, PMID: 4388242.	
RP	R89	MECHER, T. et al., "Presence of L-amino-acid oxidase in the blood in pemphigus, dermatitis herpetiformis, Duhring and herpes zoster", <i>Clin. Chim. Acta</i> , 1969, 24(1): 111-20, PubMed, PMID: 5780154.	
RP	R90	MIZON, J. et al., "Properties of turkey (<i>Meleagris gallopavo</i> L.) liver L-amino acid oxidase", <i>Biochim Biophys Acta</i> , 1970, 212(1):33-42 [article in French], PubMed, PMID 5500943.	
RP	R91	NEIMS, A.H. et al., "Distribution of D-amino acid oxidase in bovine and human nervous tissues", <i>J Neurochem.</i> , 1966, 13(3):163-8, PubMed, PMID: 4380208.	
RP	R92	NISHIKIMI, M. et al., "The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen", <i>Biochem Biophys Res Commun.</i> , 1972, 46(2):849-54, PubMed, PMID: 4400444.	
RP	R93	SHINWARI, M.A. et al., "Naturally occurring inhibition and activation of avian liver L-amino acid oxidase", 1967, 104(3): 53P - 54P, PubMed, PMID: 6049890.	
RP	R94	SINGER, S. et al., "The effects of the administration of sodium benzoate and diethylstilbestrol disulfate on the hepatic levels of several glucocorticoid-sensitive enzymes in adrenalectomized rats", <i>Biochim Biophys Acta.</i> , 1967, 146(2):443-51, PubMed, PMID: 4383683.	
RP	R95	SIVA SANKAR, D.V. et al., "The effect of chlorpromazine and of oxygen on the substrate-inhibition of L-amino acid oxidase", <i>Biochem. Med.</i> , 1975(1): 75-82, PubMed, PMID: 1212242.	
RP	R96	ZELLER, E.A. et al., "Interaction of ophidian L-amino acid oxidase with its substrates and inhibitors: role of molecular geometry and electron distribution. Communication 6 on ophidian L-amino acid oxidases", <i>Helv. Chim. Acta</i> , 1974;57(8): 2406-20, PubMed, PMID: 4443288.	
RP	R97	ZIMMERMAN, S.E. et al., "Immunochemical studies of L-amino acid oxidase", <i>Biochim Biophys Acta</i> , 1971, 229(1):260-70, PubMed, PMID: 5543611.	

Examiner Signature	Rebecca Prouty	Date Considered	2/5/05
--------------------	----------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached

+

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/211,160
		Filing Date	August 1, 2002
		First Named Inventor	Daniel Cohen
		Group Art Unit	1615
		Examiner Name	Unassigned
Sheet	1	of	1
		Attorney Docket Number	G-101US06CIP


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RP	R1	GREENE, R. "Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia", <i>Hippocampus</i> , 2001, 11(5):569-577.	
RP	R2	FUKUI, K. and Y. Miyake. "Molecular cloning and chromosomal localization of a human gene encoding D-amino-acid oxidase" <i>J. Biol. Chem.</i> , 1992, 267(26):18631-18638.	
RP	R3	MOTHET, J-P. et al. "D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor", <i>PNAS</i> , 2000, 97(9):4926-4931.	
RP	R4	HERESCO-LEVY, U. "N-methyl-D-aspartate (NMDA) receptor-based treatment approaches in schizophrenia: the first decade", <i>Intl. J. Neuropsychopharmacol</i> , 2000, 3:243-258.	
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		

Examiner Signature	Rebecca Prouty	Date Considered	2/5/05
--------------------	----------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/051,681
Filing Date	January 16, 2002
First Named Inventor	Daniel Cohen
Group Art Unit	1645
Examiner Name	Kenneth R. Horlick
Attorney Docket Number	G-101US05REG

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RP	R1	LEESON, P. et al. "The Glycine Site on the NMDA Receptor: Structure-Activity Relationships and Therapeutic Potential", November 25, 1994, pp. 4053-4067, Vol. 37, No. 24.	
RP	R2	WOOD, P. "Current Status of NMDA-Associated Glycine Site Modulators in the Treatment of Alzheimer's Disease", 1997, pp. 245-251, Vol. 2, No. 5.	
	R3		
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner
Signature

Rebecca Prouty

Date
Considered

2/5/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/051,681	
			Filing Date	January 16, 2002	
			First Named Inventor	Daniel Cohen	
			Art Unit	1645	
			Examiner Name	Kenneth R. Horlick	
Sheet	1	of	2	Attorney Docket Number	G-101US05REG

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
RP	F1	WO 01/09118	02-08-2001	Prendergast, et al.	All	
RP	F2	WO 95/01096	01-12-1995	Howard K. Shapiro	All	
RP	F3	WO 01/68104	09-20-2001	McLean Hospital Corp.	All	
	F4					
	F5					
	F6					
	F7					

Examiner Signature	Rebecca Proulx	Date Considered	2/6/05
--------------------	----------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/051,681	
			Filing Date	January 16, 2002	
			First Named Inventor	Daniel Cohen	
			Group Art Unit	1645	
			Examiner Name	Kenneth R. Horlick	
Sheet	2	of	2	Attorney Docket Number	G-101US05REG

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RP	R1	SCHORK, N.J. <i>et al.</i> "Single Nucleotide Polymorphism and the Future of Genetic Epidemiology", <i>Clinical Genetics</i> , 2000, pp. 250-264, Vol. 58, Copenhagen, DK.	
	R2		
	R3		
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		


Examiner Signature	Rebecca Proulx	Date Considered	2/5/15
--------------------	----------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
				Application Number	10/051,681
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	January 16, 2002
				First Named Inventor	Daniel Cohen
(use as many sheets as necessary)				Group Art Unit	1637
				Examiner Name	Kenneth R. Horlick
Sheet	1	of	4	Attorney Docket Number	G-101US05REG

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
RP	U1	4,279,917		Takami <i>et al.</i>	07-21-1981	All
RP	U2	4,491,589		Dell <i>et al.</i>	01-01-1985	All
RP	U3	4,604,286		Kawajiri	08-05-1986	All
RP	U4	5,605,818		Katsumata <i>et al.</i>	02-25-1997	All
RP	U5	6,013,672		Ye <i>et al.</i>	01-11-2000	All
RP	U6	6,084,084		Stormann <i>et al.</i>	07-04-2000	All
RP	U7	6,001,575		Huganir <i>et al.</i>	12-14-1999	All
RP	U8	6,362,226		Phillips, III <i>et al.</i>	03-26-2002	All
RP	U9	5,789,444		Choi <i>et al.</i>	08-04-1998	All
RP	U10	5,447,948		Seibyl <i>et al.</i>	09-05-1995	All
RP	U11	5,089,517		Choi <i>et al.</i>	02-18-1992	All
RP	U12	5,670,539		Richardson	09-23-1997	All
RP	U13	6,620,850	B2	Martynyuk <i>et al.</i>	09-16-2003	All
RP	U14	2003/0216472	A1	Martynyuk <i>et al.</i>	11-20-2003	All
	U15					
	U16					
	U17					


FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
ef	F1	WO	03/024443	A1	Univ. of Florida	03-27-2003	All	
	F2							
	F3							
	F4							
	F5							
	F6							
	F7							
	F8							
	F9							
	F10							

Examiner Signature	Rebecca Rautz	Date Considered	2/5/05
--------------------	---------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please use a plus sign (+) inside this box → ☒

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/051,681
Filing Date	January 16, 2002
First Named Inventor	Daniel Cohen
Group Art Unit	Kenneth R. Horlick
Examiner Name	1637
Attorney Docket Number	G-101US05REG

Sheet 2 of 4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RP	R1	CHIARONI, P. <i>et al.</i> "A multivariate analysis of red blood cell membrane transports and plasma levels of L-Tyrosine and L-Tryptophan in depressed patients before treatment and after clinical improvement" <i>Neuropsychobiology</i> , 1990, 23:1-7.	
RP	R2	DOLLINS, A.B. <i>et al.</i> "L-Tyrosine ameliorates some effects of lower body negative pressure stress" <i>Physiology & Behavior</i> , 1995, 57(2):223-230.	
RP	R3	EATON, S.A. <i>et al.</i> "Competitive antagonism at metabotropic glutamate receptors by (S)-4-carboxyphenylglycine and (RS)- α -methyl-4-carboxyphenylglycine" <i>European Journal of Pharmacology-Molecular Pharmacology Section</i> , 1993, 244:195-197.	
RP	R4	GAGLIARDI, R.J. "Neuroprotection, excitotoxicity and NMDA antagonists" <i>Arch Neuropsychiatr</i> , 2000, 58(2-B):583-588.	
RP	R5	GALLOWAY, G.P. <i>et al.</i> "A historically controlled trial of tyrosine for cocaine dependence" <i>Journal of Psychoactive Drugs</i> , July-September 1996, 28(3):305-309.	
RP	R6	GELENBERG, A.J. <i>et al.</i> "Neurotransmitter precursors for the treatment of depression" <i>Psychopharmacology Bulletin</i> , January 1982, 18(1):7-18.	
RP	R7	HAJAK, G. <i>et al.</i> "The influence of intravenous L-Tryptophan on plasma melatonin and sleep in men" <i>Pharmacopsychiat.</i> , 1991, 24:17-20.	
RP	R8	HELLER, B. <i>et al.</i> "Therapeutic action of D-phenylalanine in Parkinson's Disease" <i>Arzneim.-Forsch (Drug Res.)</i> , 1976, 26(4):577-579.	
RP	R9	HOLLMANN, M. <i>et al.</i> "Cloned Glutamate Receptors" <i>Annu. Rev. Neurosci.</i> , 1994, 17:31-108.	
RP	R10	KNOPFEL, T. <i>et al.</i> "Metabotropic glutamate receptors: Novel targets for drug development" <i>Journal of Medicinal Chemistry</i> , April 1995, 38(9):1417-1426.	
RP	R11	MAIESE, K. <i>et al.</i> "Group I and Group II metabotropic glutamate receptor subtypes provide enhanced neuroprotection" <i>Journal of Neuroscience Research</i> , 2000, 62:257-272.	
RP	R12	MEYER, J.S. <i>et al.</i> "Neurotransmitter precursor amino acids in the treatment of multi-infarct Dementia and Alzheimer's Disease" <i>Journal of the American Geriatrics Society</i> , July 1977, 25(7):289-298.	
RP	R13	OBRENOVITCH, T.P. "Excitotoxicity in neurological disorders—the glutamate paradox" <i>Int. J. Devl. Neuroscience</i> , 2000, 18:281-287.	

Examiner
Signature

Rebecca Ponty

Date


Considered

2/1/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

⊕ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type plus sign (+) inside this box → ☒

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/051,681
Filing Date	January 16, 2002
First Named Inventor	Daniel Cohen
Group Art Unit	Kenneth R. Horlick
Examiner Name	1637
Attorney Docket Number	G-101US05REG

Sheet 3 of 4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RP	R14	SAPOLSKY, R.M. "Cellular defenses against excitotoxic insults" <i>Journal of Neurochemistry</i> , 2001, 76:1601-1611.	
RP	R15	SCHOEPP, D.D. et al. "Metabotropic glutamate receptors in brain function and pathology" <i>TIPS</i> , January 1993, 14:13-20.	
RP	R16	SEKIYAMA, N. et al. "Structure-activity relationships of new agonists and antagonists of different metabotropic glutamate receptor subtypes" <i>British Journal of Pharmacology</i> , 1996, 117:1493-1503.	
RP	R17	WATKINS, J. et al. "Phenylglycine derivatives as antagonists of metabotropic glutamate receptors" <i>TIPS</i> , September 1994, 15:333-342.	
RP	R18	ZIPFEL, G.J. et al. "Neuronal apoptosis after CNS injury: The roles of glutamate and calcium" <i>Journal of Neurotrauma</i> , 2000, 17(10):857-869.	
RP	R19	BELARDINELLI, L. et al. "1,3-Dipropyl-8-[2-(5,6-Epoxy)Norbomyl]Xanthine, a Potent, Specific and Selective A ₁ Adenosine Receptor Antagonist in the Guinea Pig Heart and Brain and in DDT ₁ MF-2 Cells" <i>J. Pharmacol. Exp. Ther.</i> , 1995, 275(3):1167-1176.	
RP	R20	CHOI, D.W. "Excitotoxic Cell Death" <i>J. Neurobiol.</i> , 1992, 23(9):1261-1276.	
RP	R21	DENNIS, D.M. et al. "Homologous Desensitization of the A ₁ -Adenosine Receptor System in the Guinea Pig Atrioventricular Node" <i>J. Pharmacol. Exp. Ther.</i> , 1995, 272(3):1024-1035.	
RP	R22	KOSTYUK, P.G. et al. "Effects of intracellular administration of L-tyrosine and L-phenylalanine on voltage-operated calcium conductance in PC12 pheochromocytoma cells" <i>Brain Res.</i> , 1991, 550:11-14.	
RP	R23	KRYSTAL, J.H. et al. "NMDA Agonists and Antagonist as Probes of Glutamatergic Dysfunction and Pharmacotherapies in Neuropsychiatric Disorders" <i>Harv. Rev. Psychiatry</i> , Sept.-Oct. 1999, 7(3):125-143.	
RP	R24	LIPTON, S.A. and P.A. ROSENBERG "Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders" <i>N. Engl. J. Med.</i> , 1994, 330(9):613-622.	
RP	R25	MARTYNYUK, A.E. et al. "Blocking effect of intraperitoneal injection of phenylalanine on high-threshold calcium currents in rat hippocampal neurons" <i>Brain Res.</i> , 1991, 552:228-231.	
RP	R26	MARTYNYUK, A.E. et al. "Adenosine increases potassium conductance in isolated rabbit atrioventricular nodal myocytes" <i>Cardiovasc. Res.</i> 1995, 30:668-675.	

Examiner
Signature

Rebecca Prouty


Date
Considered

2/15/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type plus sign (+) inside this box → ☒

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete If Known

Application Number	10/051,681
Filing Date	January 16, 2002
First Named Inventor	Daniel Cohen
Group Art Unit	Kenneth R. Horlick
Examiner Name	1637
Attorney Docket Number	G-101US05REG

Sheet 4 of 4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RP	R27	MARTYNYUK, A.E. <i>et al.</i> "Hyperkalemia Enhances the Effect of Adenosine on I _{K,ADO} in Rabbit Isolated AV Nodal Myocytes and on AV Nodal Conduction in Guinea Pig Isolated Heart" <i>Circulation</i> , 1999, 99:312-318.	
RP	R28	MOREY, T.E. <i>et al.</i> "Structure-Activity Relationships and Electrophysiological Effects of Short-Acting Amiodarone Homologs in Guinea Pig Isolated Heart" <i>J. Pharmacol. Exp. Ther.</i> , 2001, 297(1):260-266.	
RP	R29	MOREY, T.E. <i>et al.</i> "Ionic Basis of the Differential Effects of Intravenous Anesthetics on Erythromycin-Induced Prolongation of Ventricular Repolarization in the Guinea Pig Heart" <i>Anesthesiology</i> , 1997, 87:1172-1181.	
RP	R30	SEUBERT, C.N. <i>et al.</i> "Midazolam Selectively Potentiates the A _{2A} , but not A ₁ , receptor-mediated Effects of Adenosine" <i>Anesthesiology</i> , 2000, 92:567-577.	
RP	R31	TANAKA, H. <i>et al.</i> "The AMPAR subunit GluR2: still front and center-stage" <i>Brain Res.</i> , 2000, 886:190-207.	
RP	R32	WEISS, J.H. and S.L. SENSI "Ca ²⁺ -Zn ²⁺ permeable AMPA or kainite receptors: possible key factors in selective neurodegeneration" <i>Trends Neurosci.</i> , 2000, 23(8):365-371.	
RP	R33	ZIMA, A. <i>et al.</i> "Antagonism of the Positive Dromotropic Effect of Isoproterenol by Adenosine: Role of Nitric Oxide, cGMP-dependent camp-phosphodiesterase and Protein Kinase G" <i>J. Mol. Cell. Cardiol.</i> , 2000, 32:1609-1619.	
RP	R34	GLUSHAKOV, A.V. <i>et al.</i> "L-phenylalanine selectively depresses currents at glutamatergic excitatory synapses" <i>J. Neurosci. Res.</i> , 2003, 72:116-124.	
RP	R35	GLUSHAKOV, A.V. <i>et al.</i> "Specific inhibition of N-methyl-D-aspartate receptor function in rat hippocampal neurons by L-phenylalanine at concentrations observed during phenylketonuria" <i>Molecular Psychiatry</i> , 2002, 7:359-367.	
RP	R36	LIECHTY, E.A. <i>et al.</i> "Aromatic amino acids are utilized and protein synthesis is stimulated during amino acid infusion in the ovine fetus" <i>J. Nutrition</i> , 1999, 129:1161-1166.	
	R37		
	R38		
	R39		

Examiner
Signature

Rebecca Prouty

Date

Considered

2/5/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

DEC 16 2002

PTO/SB/08A (10-01)
 Approved for use through 10/31/2002. OMB 0651-0031
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/051,681	
			Filing Date	January 16, 2002	
			First Named Inventor	D. COHEN, et al.	
			Art Unit	1645	
			Examiner Name	Unassigned	
Sheet	1	of	10	Attorney Docket Number	101.US5.REG

TECH CENTER 160012900

JAN 02 2003

RECEIVED

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. 1	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code 2 (if known)				
R P P P P P P P P P P P P P	U1	US-	6.184.218 B1	02/06/2001	Evenden, et al.	
	U2	US-	6.218.544 B1	04/17/2001	Li, et al.	
	U3	US-	6.214.846 B1	04/10/2001	Elliott	
	U4	US-	6.232.326	05/15/2001	Nelson	
	U5	US-	6.174.909	01/16/2001	Falch, et al.	
	U6	US-	5.965.571	10/12/1999	Hutchinson	
	U7	US-	5.610.195	03/11/1997	Frei, et al.	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
	US-					

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No. 1	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code 3 - Number 4 - Kind Code 5 (if known)					
	F1	WO	00/22122 A2	04/20/2000	Genset		
	F2	WO	01/40493 A2	06/07/2001	Genset		
	F3	WO	00/58510 A2	10/05/2000	Genset		

Examiner Signature	Rebecca Proulx	Date Considered	2/5/05
-----------------------	----------------	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

01/11/2002

PTO/SB/088 (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/051.681
		Filing Date	January 16, 2002
		First Named Inventor	D. COHEN, et al.
		Group Art Unit	1645
		Examiner Name	Unassigned
		Attorney Docket Number	101.US5.REG
Sheet	2	of	10

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	?
	R1	ALSTON, T. et al. "Suicide inactivation of D-amino acid oxidase by 1-chloro-1-nitroethane"; The Journal of Biological Chemistry, Vol 258, N°2 : 1136-41, January 25, 1983	
	R2	BARAM, T. and al. "CRH gene expression in the fetal rat is not increased after pharmacological adrenalectomy"; Neuroscience Letters, Vol 142 : 215-8, 1992	
	R3	BARANANO, D. et al. "Atypical neural messengers"; Trends in Neurosciences, Vol 24, N°2 : 99-106, February 2001	
	R4	BRACHET, P. et al. "Kinetics of the inhibition of hog kidney D-amino acid oxidase by short-, medium- and long-chain fatty acids"; Biochemistry International, Vol 22, N°5 : 837-42, December 1990	
	R5	CHUN, W. et al. "Tissue transglutaminase selectively modifies proteins associated with truncated mutant Huntingtin in intact cells"; Neurobiology of Disease, Vol 8 : 391-404, 2001	
	R6	D'ANIELLO, A. et al. "Biological role of D-amino acid oxidase and D-aspartate oxidase effects of D-amino acids"; The Journal of Biological Chemistry, Vol 268, N°36 : 25841-9, December 25, 1993	
	R7	D'ANIELLO, A. et al. "Further study on the specificity of D-amino acid oxidase and of D-aspartate oxidase and time course for complete oxidation of D-amino acids"; Comp. Biochem. Physiol., Vol 105B, N°3/4 : 731-4, 1993	
	R8	DIXON, M. et al. "D-amino acid oxidase - I. Dissociation and recombination of the holoenzyme"; Biochimica et Biophysica Acta, Vol 96 : 357-67, 1965	
	R9	D'SILVA, C. et al. "Identification of methionine-110 as the residue covalently modified in the electrophilic inactivation of D-amino acid oxidase by O-(2,4-dinitrophenyl) hydroxylamine"; Biochemistry, Vol 26 : 1717-22, 1987	
	R10	DOOT, G. et al. "The human L-pipecolic acid oxidase is similar to bacterial monomeric sarcosine oxidases rather than D-amino acid oxidases"; Cell Biochemistry and Biophysics, Vol 32 : 313-6, 2000	
	R11	FERTI, C. et al. "Reactivity of D-amino acid oxidase with 1,2-cyclohexanedione : evidence for one arginine in the substrate-binding site". Eur J Biochem, Vol 119 : 553-7, 1981	

Examiner Signature	<i>Rebecca Poretsky</i>	Date Considered	2/5/05
--------------------	-------------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
JAN 16 2 2003
TECH CENTER 160012900

DEC 30 2002

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/051.681
		Filing Date	January 16, 2002
		First Named Inventor	D. COHEN, et al.
		Group Art Unit	1645
		Examiner Name	Unassigned
		Attorney Docket Number	101.US5.REG
Sheet	3	of	10

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T?
	R12	FONDA, M., et al. "D-amino acid oxydase"; The Journal of Biological Chemistry, Vol 243, N°8 : 1931-5, April 25, 1968	
	R13	KRAUS, J.L., et al. "Tetrazole isosteres of biologically active acids and their effects on enzymes"; Research Communications in Chemical Pathology and Pharmacology, Vol 83, N°2 : 209-22, February 1994	
	R14	GADDA, G., et al. "Characterization of 2-oxo-3-pentynoate as an active-site-directed inactivator of flavoprotein oxidases : identification of active-site peptides in tryptophan 2-monooxygenase"; Biochemistry, Vol 38 : 5822-28, 1999	
	R15	GADDA, G., et al. "Chemical modification of lysyl residues of Rhodotomula gracilis D-amino acid oxydase"; Biochemistry and Molecular Biology International, Vol 33, N°5, 947-55, August 1994	
	R16	HAMILTON, G., et al. "The inhibition of mammalian D-amino acid oxydase by metabolites and drugs. Inferences concerning physiological function"; Bioorganic Chemistry, Vol 11 : 350-70, 1982	
	R17	HASHIMOTO, A., et al. "Free D-aspartate and D-serine in the mammalian brain and periphery"; Progress in Neurobiology, Vol 52 : 325-53, 1997	
	R18	HASHIMOTO, A., et al. "Free D-serine, D-aspartate and D-alanine in central nervous system and serum in mutant mice lacking D-amino acid oxydase"; Neuroscience Letters, Vol 152 : 33-6, 1993	
	R19	HASHIMOTO, A., et al. "Embryonic development and postnatal changes in free D-aspartate and D-serine in the human prefrontal cortex"; Journal of Neurochemistry, Vol 61 : 348-51, 1993	
	R20	HORIIE, K., et al. "Interaction between D-amino acid oxydase and small molecules"; Journal of Biochemistry, Vol 80 : 1073-83, 1976	
	R21	HUANG, J., et al. "Hepatocyte-catalysed detoxification of cyanide by L- and D-cysteine"; Biochemical Pharmacology, Vol 55 : 1883-90, 1998	
	R22	KAPOOR R., et al. "Distribution of D-amino acid oxydase (DAO) activity in the medulla and thoracic spinal cord of the rat : implications for a role for D-serine in autonomic function"; Brain Research, Vol 771 : 351-55, 1997	

Examiner Signature	<i>Rebecca Proulx</i>	Date Considered	2/5/05
--------------------	-----------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

TECH CENTER 1600/2900

JAN 02 2003

RECEIVED

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/051.681
		Filing Date	January 16, 2002
		First Named Inventor	D. COHEN, et al.
		Group Art Unit	1645
		Examiner Name	Unassigned
		Attorney Docket Number	101.US5.REG
Sheet	4	of	10

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	R23	KONNO, R, et al. "Mouse mutant deficient in D-amino acid oxidase activity"; Genetics, Vol 103 : 277-85, February 1983	
	R24	MARCOTTE, P, et al. "Sequence of reactions which follows enzymatic oxidation of allylglycine"; Biochemistry, Vol 17, N° 26 : 5620-6, 1978	
	R25	MARCOTTE, P, et al. "Vinylglycine and propargylglycine : complementary suicide substrates for L-amino acid oxidase and D-amino acid oxidase"; Biochemistry, Vol 15, N°14 : 3070-5, 1976	
	R26	MASSEY, V, et al. "On the interpretation of the absorption spectra of flavoproteins with special reference to D-amino acid oxidase"; Biochemistry, Vol 4, N°6 : 1161-73, June 1965	
	R27	ROBINSON, JM, et al. "Localization of D-amino acid oxidase on the cell surface of human polymorphonuclear leukocytes"; J Cell Biology, Vol 77 : 59-71 1978	
	R28	MATTEVI, A "The PHBH fold : not only flavoenzymes"; Biophysical Chemistry, Vol 70 : 217-22, 1998	
	R29	MATTEVI, A, et al. "Crystal structure of D-amino acid oxidase : a case of active site mirror-image convergent evolution with flavocytochrome b2"; Proc. Natl. Acad. Sci. USA, Vol 93 : 7496-501, July 1996	
	R30	MELDRUM, BS, et al. "Proconvulsant, convulsant and other actions of the D- and L-stereoisomers of allylglycine in the photosensitive baboon, papio papio"; Electroencephalography and Clinical Neurophysiology, Vol 47 : 383-95, 1979	
	R31	MIHALIK, S, et al. "L-pipecolic acid oxidation in the rabbit and cynomolgus monkey"; The Journal of Biological Chemistry, Vol 264, N°5 : 2589-17, February 15, 1989	
	R32	MIURA, R, et al. "Studies on the reaction of D-amino acid oxidase with beta-cyano-D-alanine"; J Biochem, Vol 87, N°5 : 1469-81, 1980	
	R33	MIURA, R, et al. "C-NMR studies of porcine kidney D-amino acid oxidase reconstituted with C-enriched flavin adenine dinucleotide. Effects of competitive inhibitors"; J Biochem, Vol 101, N°3 : 581-9, 1987	

Examiner Signature	<i>Rebecca Pouty</i>	Date Considered	2/5/05
--------------------	----------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

JAN 0 2 2003

TECH CENTER 160012900

RECEIVED

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/051.681
		Filing Date	January 16, 2002
		First Named Inventor	D. COHEN, et al.
		Group Art Unit	1645
		Examiner Name	Unassigned
Sheet	5	of	10
		Attorney Docket Number	101.US5.REG

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	R34	MIYANO, M, et al. "Studies on Phe-228 and Leu-307 recombinant mutants of porcine kidney D-amino acid oxidase: expression, purification and characterization"; J. Biochem., Vol 109, N°1: 171-7, 1991	
	R35	MORENO, JA, et al. "Inhibition of D-amino acid oxidase by alpha-keto acids analogs of amino acids"; Enzyme and Microbial Technology, Vol 18: 379-82, 1996	
	R36	MOSES, J, et al. "Sodium benzoate differentially blocks circling induced by D- and L- dopa in the hemi-parkinsonian rat"; Neuroscience Letters, Vol 218: 195-8, 1996	
	R37	SHIN-ISHI, N, et al. "High-dose ketamine does not induce c-Fos protein expression in rat hippocampus"; Neuroscience Letters, Vol 151: 33-6, 1993	
	R38	NEGRI, A, et al. "The kinetic mechanism of beef kidney D-aspartate oxidase"; The Journal of Biological Chemistry, Vol 263: 13557-63, September 25, 1988	
	R39	NISHINO, T, et al. "Chemical modifications of D-amino acid oxidase"; The Journal of Biological Chemistry, Vol 255, N°8: 3610-6, April 25, 1980	
	R40	NISHINA, Y, et al. "Substrate recognition and activation mechanism of D-amino acid oxidase: a study using substrate analogs"; J. Biochem., Vol 126, N°2: 213-23, 2000	
	R41	PORTER, D, et al. "Active site chlorination of D-amino acid oxidase by N-chloro-D-leucine"; The Journal of Biological Chemistry, Vol 251, N°19: 6150-3, October 10, 1976	
	R42	RAMON, F, et al. "Chemical mechanism of D-amino acid oxidase from Rhodotorula gracilis: pH dependence of kinetic parameters"; Biochem. J., Vol 330: 311-4, 1998	
RP	R43	RICCI, G, et al. "Interaction between 1,4-thiazine derivatives and D-amino-acid oxidase"; Biochimica et Biophysica Acta, Vol 748: 40-7, 1983	
RP	R44	SHELL, M, et al. "D-aspartate localizations imply neuronal and neuroendocrine roles"; Proc. Natl. Acad. Sci. USA, Vol 94: 2013-8, March 1997	

Examiner Signature	<i>Rebecca Prouty</i>	Date Considered	2/5/05
--------------------	-----------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

TECH CENTER 1600/2900

JAN 02 2003

RECEIVED

100

PTO/SB/088 (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

+

Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/051.681		
		Filing Date	January 16, 2002		
		First Named Inventor	D. COHEN, et al.		
		Group Art Unit	1645		
		Examiner Name	Unassigned		
Sheet	6	of	10	Attorney Docket Number	101.US5.REG

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T2
RP	R45	SHELL, M, et al. "D-serine as a neuromodulator: regional and developmental localizations in rat brain glia resemble NMDA receptors"; The Journal of Neuroscience, Vol 17, N°5 : 1604-15, March 1, 1997	
	R46	SETOYAMA, C, et al. "Structural and functional characterization of the human brain D-aspartate oxidase"; J. Biochem, Vol 124, N°4 : 798-803, 1997	
	R47	SNYDER, SH, et al. "D-amino acids as putative neurotransmitters: focus on D-serine"; Neurochemical Research, Vol 25, N°5 : 553-60, 2000	
	R48	SWENSON, RP, et al. "Methylation of the active center histidine 217 in D-amino acid oxidase by Methyl-p-nitrobenzenesulfonate"; The Journal of Biological Chemistry, Vol 259, N°9 : 5585-90, May 10, 1984	
	R49	SWENSON, RP, et al. "Chemical modification of D-amino acid oxidase"; The Journal of Biological Chemistry, Vol 257, N°4 : 1937-44, February 25, 1982	
	R50	TANAKA, F, et al. "Interaction of steroids with D-amino acid oxidase"; Biochimica et Biophysica Acta, Vol 522 : 43-8, 1978	
	R51	VAMECQ, J, et al. "Inhibition of peroxisomal fatty acyl-CoA oxidase by antimycin A"; Biochem J., Vol 248 : 603-7, 1987	
	R52	VAN VELDHOVEN, P, et al. "D-aspartate oxidase, a peroxisomal enzyme in liver of rat and man"; Biochimica et Biophysica Acta, Vol 1073 : 203-8, 1991	
	R53	WANG, H, et al. "Regulation of rat magnocellular neurosecretory system by D-aspartate: evidence for biological role(s) of a naturally occurring free D-amino acid in mammals"; Journal of Endocrinology, Vol 167 : 247-52, 2000	
	R54	WATANABE, F, et al. "Site-specific mutagenesis of lysine-204, tyrosine-224, tyrosine-228, and histidine-307 of porcine kidney D-amino acid oxidase and the implications as to its catalytic function"; J. Biochem, Vol 105, N°6 : 1024-9, 1989	
R55	WINSTEAD, JA, et al. "Gamma-irradiated flavin adenine dinucleotide: a D-amino acid oxidase inhibitor"; Radiation Research, Vol 52 : 520-7, 1972		

Examiner Signature	<i>Rebecca Prouty</i>	Date Considered	2/5/05
--------------------	-----------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

TECH CENTER 1600/2900

JAN 02 2003

RECEIVED

151 4 8 2002

PTO/SB/088 (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO			Complete If Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/051.681	
			Filing Date	January 16, 2002	
			First Named Inventor	D. COHEN, et al.	
			Group Art Unit	1645	
			Examiner Name	Unassigned	
Sheet	7	of	10	Attorney Docket Number	101.US5.REG

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	R56	AMERY, L, et al. "C-terminal tripeptide Ser-Asn-Leu (SNL) of human D-aspartate oxidase is a functional peroxisome-targeting signal"; Biochem J, Vol 336 : 367-71, 1998 - ABSTRACT	
	R57	ARMATI, PJ, et al. "A new medium for in vitro peripheral nervous tissue myelination without the use of antimetabolites"; J Neurosci Methods, Vol 33 (2-3) : 149-55, 1990 - ABSTRACT	
	R58	ARNOLD, G, et al. "Ultrastructural localization of D-amino acid oxidase in microperoxisomes of the rat nervous system"; J Histochem Cytochem, Vol 27(3) : 735-45, 1979 - ABSTRACT	
	R59	ASSI, AA, et al. "An in vitro and in vivo study of some biological and biochemical effects of Sistrurus Malariae Barbouri venom"; Toxicology, Vol 137(2) : 81-94, 1999 - ABSTRACT	
	R60	BEARD, ME "D-aspartate oxidation by rat and bovine renal peroxisomes : an electron microscopic cytochemical study"; J Histochem Cytochem, Vol 38(9) : 1377-84, 1990 - ABSTRACT	
	R61	CIMINI, AM, et al. "Presence of heterogeneous peroxisomal populations in the rat nervous tissue"; Biochim Biophys Acta, Vol 1425(1) : 13-26, 1998 - ABSTRACT	
	R62	COOPER, AJ, et al. "Inhibition of glutamate-aspartate transaminase by beta-methylene-DL-aspartate"; Biochem Pharmacol, Vol 32(4) : 679-89, 1989 - ABSTRACT	
	R63	D'ANIELLO, G, et al. "The role of D-aspartic acid and N-methyl-D-aspartic acid in the regulation of prolactin release"; Endocrinology, Vol 141(10) : 3862-70, 2000 - ABSTRACT	
	R64	D'ANIELLO, G, et al. "Occurrence of free D-aspartic acid in the circumoesophageal ganglia of Aplysia fasciata"; Life Sci, Vol 52(8) : 733-6, 1993 - ABSTRACT	
	R65	DE MORAES, GH, et al. "Effects of D-amino acids on growth rate and kidney D-amino acid oxidase in chicks"; Poult Sci, Vol 66(1) : 98-102, 1987 - ABSTRACT	
	R66	FISHER, GH, et al. "Quantification of D-aspartate in normal and Alzheimer brains"; Neurosci Lett, Vol 143(1-2) : 115-8, 1992 - ABSTRACT	

Examiner Signature	<i>Rebecca Prody</i>	Date Considered	2/5/05
--------------------	----------------------	-----------------	--------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

TECH CENTER 1600/2900

JAN 0 2 2003

RECEIVED

03: 10 2003

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
		Application Number	10/051.681
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	January 16, 2002
		First Named Inventor	D. COHEN, et al.
		Group Art Unit	1645
		Examiner Name	Unassigned
		Attorney Docket Number	101.US5.REG
Sheet	8	of	10

TECH CENTER 1600/2900

JAN 02 2003

RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	7?
	R67	GILBERT, SF, et al. "Selective culture medium enhances survival of neuroblasts from postnatal rodent brain"; Brain Res Bull, Vol 16(6) : 853-60, 1986 - ABSTRACT	
	R68	HASHIMOTO, A, et al. "Anatomical distribution and postnatal changes in endogenous free D-aspartate and D-serine in rat brain and periphery"; Eur J Neurosci, Vol 7(8) : 1657-63, 1995 - ABSTRACT	
	R69	HASHIMOTO, A, et al. "Embryonic development and postnatal changes in free D-aspartate and D-serine in the human prefrontal cortex"; J Neurochem, Vol 61(1) : 348-51, 1993- ABSTRACT	
	R70	NARDINI, M, et al. "Detection of 2H-1,4-thiazine-5,6-dihydro-3-carboxylic acid (aminoethylcysteine ketimine) in the bovine brain"; Biochem Biophys Res Commun, Vol 166(3) : 1251-6, 1990 - ABSTRACT	
	R71	NEGRI, A, et al. "D-aspartate oxidase from beef kidney. Purification and properties"; J Biol Chem, Vol 262(21) : 10026-34, 1987 - ABSTRACT	
	R72	NEGRI, A, et al. "Purification of beef kidney D-aspartate oxidase overexpressed in Escherichia coli and characterization of its redox potentials and oxidative activity towards agonists and antagonists of excitatory amino acid receptors"; Biochim Biophys Acta, Vol 1427(1) : 212-22, 1999 - ABSTRACT	
	R73	PERRY, RH, et al. "Cortical neuropathological and neurochemical substrates of Alzheimer's and Parkinson's diseases"; J Neural Trans Suppl, Vol 24/131-6, 1987 - ABSTRACT	
	R74	SHAPIRA, R, et al. "Neuritic plaque amyloid in Alzheimer's disease is highly racemized"; J Neurochem, Vol 50(1) : 69-74, 1988 - ABSTRACT	
	R75	SIKORA, L, et al. "Regulation of L-amino acid oxidase and of D-amino acid oxidase in Neurospora crassa"; Mol Gen Genet, Vol 186(1) : 33-9, 1982 - ABSTRACT	
	R76	TAKATSUKA, H, et al. "Molecular characterization of L-amino acid oxidase from Agkistrodon halys blomhoffii with special reference to platelet aggregation"; Biochim Biophys Acta, Vol 1544(1-2) : 267-77, 2001 - ABSTRACT	
	R77	TEDESCHI, G, et al. "D-aspartate oxidase is present in ovaries, eggs and embryos but not in testis of Xenopus laevis"; Comp Biochem Physiol B Biochem Mol Biol, Vol 124(4) : 489-94, 1999 - ABSTRACT	

Examiner Signature	Rebecca Proulx	Date Considered	2/15/05
--------------------	----------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/051,681	
Sheet	9	of	10	Filing Date	January 16, 2002
				First Named Inventor	D. Cohen et al.
				Group Art Unit	1645
				Examiner Name	unassigned
				Attorney Docket Number	101.US5.REG

TECH CENTER 1600 2900

JAN 02 2003

RECEIVED

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R78	TEDESCHI, G. et al., "Properties of the flavoenzyme D-aspartate oxidase from Octopus vulgaris", <i>Biochim Biophys Acta</i> , Vol. 1207(2): 217-22 (1994) - ABSTRACT	
	R79	TORII, S. et al., "Molecular cloning and functional analysis of apoxin I, a snake venom-derived apoptosis-inducing factor with L-amino acid oxidase activity", <i>Biochemistry</i> , Vol. 39(12): 3197-205 (2000) - ABSTRACT	
	R80	WAKE, K. et al., "Exaggerated responses to chronic nociceptive stimuli and enhancement of N-methyl-D-aspartate receptor-mediated synaptic transmission in mutant mice lacking D-amino-acid oxidase", <i>Neurosci. Lett.</i> , Vol. 297(1): 25-8 (2001) - ABSTRACT	
	R81	YAMADA, R., et al., "Purification and properties of D-aspartate oxidase from <i>Cryptococcus humicola</i> UJ1", <i>Biochim Biophys Acta</i> , Vol. 1294(2): 153-8 (1996) - ABSTRACT.	
	R82	BARKER, R. et al., "The genetic and biochemical properties of the D-amino acid oxidases in human tissues", <i>Ann. Hum. Genet.</i> , 41(1): 27-42 (1997), Accession No. 004032.	
	R83	MOMOI, K. et al., "Molecular cloning and sequence analysis of kidney D-amino acid oxidase", <i>FEBS Lett.</i> , 238: 180-184 (1988), Accession No. P14920.	
	R84	SETOYAMA, C. et al., "Structural and functional characterization of the human brain D-aspartate oxidase", <i>J. Biochem.</i> , 121(4): 798-803 (1997), Accession No. JC5438.	
	R85	CRUZ, L.J. et al., "Mutual antagonism in the metabolism of D-valine and D-leucine and antagonism by their analogs", <i>Arch Biochem Biophys.</i> , 1969, 135(1):341-9, PubMed, PMID: 4391341.	
	R86	DE KOK, A. et al., "Studies on L-amino acid oxidase. I. Effects of pH and competitive inhibitors", <i>Biochim Biophys Acta</i> , 1968, 167(1): 35-47, PubMed, PMID: 5693709.	
	R87	DE MARCHI, W.J. et al., "The oxidation of glycine by D-amino acid oxidase in extracts of mammalian central nervous tissue", <i>J Neurochem.</i> , 1969, 16(3):355-61. PubMed, PMID: 4389537.	
	R88	MCFARIANE, I.G. et al., "Metabolism of leucine in protein-calorie-deficient rats", <i>Biochem J.</i> , 1969, 111(4):565-71, PubMed, PMID: 4388242.	
	R89	MEZGER, T. et al., "Presence of L-amino-acid oxidase in the blood in pemphigus, dermatitis herpetiformis Dühring and herpes zoster", <i>Clin. Chim. Acta</i> , 1969, 24(1): 111-20, PubMed, PMID: 5780154.	

Examiner Signature	<i>Rebecca Pong</i>	Date Considered	2/5/05
--------------------	---------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

157 1 0 2002

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

+ RECEIVED

TECH CENTER 1600 1200

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/051,681	
			Filing Date	January 16, 2002	
			First Named Inventor	D. Cohen et al.	
			Group Art Unit	1645	
			Examiner Name	unassigned	
Sheet	10	of	10	Attorney Docket Number	101.US5.REG

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R90	MIZON, J. et al., "Properties of turkey (Meleagris gallopavo L.) liver L-amino acid oxidase", <i>Biochim Biophys Acta</i> , 1970, 212(1):33-42 [article in French], PubMed, PMID 5500943.	
	R91	NEIMS, A.H. et al., "Distribution of D-amino acid oxidase in bovine and human nervous tissues", <i>J Neurochem.</i> 1966, 13(3):163-8, PubMed, PMID: 4380208.	
	R92	NISHIKIMI, M. et al., "The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen", <i>Biochem Biophys Res Commun.</i> , 1972, 46(2):849-54, PubMed, PMID: 4400444.	
	R93	SHINWARI, M.A. et al., "Naturally occurring inhibition and activation of avian liver L-amino acid oxidase", 1967, 104(3): 53P - 54P, PubMed, PMID: 6049890.	
	R94	SINGER, S. et al., "The effects of the administration of sodium benzoate and diethylstilbestrol disulfate on the hepatic levels of several glucocorticoid-sensitive enzymes in adrenalectomized rats", <i>Biochim Biophys Acta.</i> , 1967, 146(2):443-51, PubMed, PMID: 4383683.	
	R95	SIVA SANKAR, D.V. et al., "The effect of chlorpromazine and of oxygen on the substrate-inhibition of L-amino acid oxidase", <i>Biochem. Med.</i> , 1975(1): 75-82, PubMed, PMID: 1212242.	
	R96	ZELLER, E.A. et al., "Interaction of ophidian L-amino acid oxidase with its substrates and inhibitors: role of molecular geometry and electron distribution. Communication 6 on ophidian L-amino acid oxidases", <i>Helv. Chim. Acta</i> , 1974;57(8): 2406-20, PubMed, PMID: 4443288.	
	R97	ZIMMERMAN, S.E. et al., "Immunochemical studies of L-amino acid oxidase", <i>Biochim Biophys Acta</i> , 1971, 229(1):260-70, PubMed, PMID: 5543611.	
	R98		
	R99		
	R100		
	R101		

Examiner Signature	Rebecca Proulx	Date Considered	2/5/05
--------------------	----------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.